| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $8.3M | +68.9% |
| SG&A Expense | $150.1M | +34.7% |
| Operating Income | -$171.1M | -39.5% |
| Interest Expense | $87.5M | +74.1% |
| Net Income | $277.4M | +225.2% |
| EPS (Basic) | -$0.24 | +74.5% |
| EPS (Diluted) | -$0.24 | +74.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $148.1M | +287.4% |
| Current Assets | $412.6M | +31.2% |
| Total Assets | $6.40B | +92.7% |
| Current Liabilities | $595.1M | +7.7% |
| Long-term Debt | $4.04B | +122.2% |
| Total Liabilities | $4.66B | +80.4% |
| Stockholders' Equity | $377.6M | +31.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$95.6M | -29.8% |
| Capital Expenditures | $2.57B | +47.8% |
| Investing Cash Flow | -$2.57B | -46.9% |
| Financing Cash Flow | $2.77B | +34.5% |
| Free Cash Flow | -$2.66B | -47.0% |